title: Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry.
abstract: Using two in vivo methods, microdialysis and rapid in situ electrochemistry, this study examined the modulation of extracellular glutamate levels by endogenously produced kynurenic acid (KYNA) in the prefrontal cortex (PFC) of awake rats. Measured by microdialysis, i.p. administration of KYNA's bioprecursor L-kynurenine dose-dependently elevated extracellular KYNA and reduced extracellular glutamate (nadir after 50 mg/kg kynurenine: 60% decrease from baseline values). This dose-dependent decrease in glutamate levels was also seen using a glutamate-sensitive microelectrode array (MEA) (31% decrease following 50 mg/kg kynurenine). The kynurenine-induced reduction in glutamate was blocked (microdialysis) or attenuated (MEA) by co-administration of galantamine (3 mg/kg i.p.), a drug that competes with KYNA at an allosteric potentiating site of the alpha 7 nicotinic acetylcholine receptor. In separate experiments, extracellular glutamate levels were measured by MEA following the local perfusion (45 min) of the PFC with kynurenine (2.5 microM) or the selective KYNA biosynthesis inhibitor S-ethylsulfonylbenzoylalanine (S-ESBA; 5 mM). In agreement with previous microdialysis studies, local kynurenine application produced a reversible reduction in glutamate (nadir: -29%), whereas perfusion with S-ESBA increased glutamate levels reversibly (maximum: +38%). Collectively, these results demonstrate that fluctuations in the biosynthesis of KYNA in the PFC bi-directionally modulate extracellular glutamate levels, and that qualitatively very similar data are obtained by microdialysis and MEA. Since KYNA levels are elevated in the PFC of individuals with schizophrenia, and since prefrontal glutamatergic and nicotinic transmission mediate cognitive flexibility, normalization of KYNA levels in the PFC may constitute an effective treatment strategy for alleviating cognitive deficits in schizophrenia.
authors.affiliation: Department of Psychology, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: A
authors.initials: A
authors.lastname: Konradsson-Geuken
authors.forename: H Q
authors.initials: HQ
authors.lastname: Wu
authors.forename: C R
authors.initials: CR
authors.lastname: Gash
authors.forename: K S
authors.initials: KS
authors.lastname: Alexander
authors.forename: A
authors.initials: A
authors.lastname: Campbell
authors.forename: Y
authors.initials: Y
authors.lastname: Sozeri
authors.forename: R
authors.initials: R
authors.lastname: Pellicciari
authors.forename: R
authors.initials: R
authors.lastname: Schwarcz
authors.forename: J P
authors.initials: JP
authors.lastname: Bruno
mesh_terms: D000818:Animals; D001923:Brain Chemistry / Q000502:physiology*; D055664:Electrochemical Techniques / Q000379:methods*; D018698:Glutamic Acid / Q000378:metabolism*; D007736:Kynurenic Acid / Q000378:metabolism*; D008297:Male; D017551:Microdialysis / Q000379:methods*; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D018698:Glutamic Acid; D007736:Kynurenic Acid